Therapeutic area
Respiratory biotech companies
The 1 respiratory company we cover, with cash and runway from their latest SEC filings, trial milestones from ClinicalTrials.gov, and FDA decisions from their own 8-Ks. Companies are tagged by the areas their pipelines target.
Companies
| Company | Most advanced program | Cash & investments | Runway | Profile |
|---|---|---|---|---|
| ARWRArrowhead Pharmaceuticals | Plozasiran · familial chylomicronemia syndromeApproved | no filing parsed | — | archived |
Runway is cash divided by quarterly operating burn and is not shown for companies funded by their own revenue. Figures and their dates are on each company page, linked to the filing.
Upcoming trial milestones
- 2027-08-20 · ARWR · YOSEMITE: Zodasiran in Homozygous familial hypercholesterolemia — primary completion ClinicalTrials.gov
- 2028-07 · ARWR · SHASTA-10: Plozasiran in Hypertriglyceridemia (open-label extension) — primary completion ClinicalTrials.gov
- 2029-03 · ARWR · SHASTA-5: Plozasiran in Severe hypertriglyceridemia at high risk of acute pancreatitis — primary completion ClinicalTrials.gov
A registry milestone is the date data collection is scheduled to end, not the date results are released.
FDA decisions
None of these companies has an FDA decision on our PDUFA calendar, which lists only dates a company has stated in a filing.
Educational information, not investment advice. See where each field comes from.